AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - Results of two parallel first-in-human phase I studies

Investigational New Drugs

Volumn 33, Issue 3, 2015, Pages 679-690

  Omlin, A ^a   Jones, R J ^b   Van Der Noll, R ^c   Satoh, T ^d   Niwakawa, M ^e   Smith, S A ^f   Graham, J ^b   Ong, M ^a   Finkelman, R D ^f   Schellens, J H M ^c,g   Zivi, A ^a   Crespo, M ^a   Riisnaes, R ^a   Nava Rodrigues, D ^a   Malone, M D ^f   Dive, C ^j   Sloane, R ^j   Moore, D ^j   Alumkal, J J ^h   Dymond, A ^f   Dickinson, P A ^f   Ranson, M ⁱ   Clack, G ^f   De Bono, J ^a   Elliott, T ⁱ   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f ASTRAZENECA   (United Kingdom)

^g UTRECHT UNIVERSITY   (Netherlands)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

(5) Castration resistant prostate cancer; AZD3514; First in human; Phase I; Selective androgen receptor down regulator

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; AZD3514; PROSTATE SPECIFIC ANTIGEN; PYRIDAZINE DERIVATIVE;

AGED; CLINICAL TRIAL; DOSE RESPONSE; DOWN REGULATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOGRAPHY; TUMOR EMBOLISM; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRIDAZINES; RECEPTORS, ANDROGEN;

EID: 84937758058     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0235-5     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300. doi: 10.3322/caac.20073
2. Attard G, Cooper CS, de Bono JS (2009) Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16(6):458-462. doi: 10.1016/j.ccr.2009.11.006
3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005. doi: 10.1056/NEJMoa1014618
4. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138-148. doi: 10.1056/NEJMoa1209096
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187-1197. doi: 10.1056/NEJMoa1207506
6. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. doi: 10.1056/NEJMoa1405095
7. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN (2013) Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol: Off J Eur Soc Med Oncol ESMO. doi: 10.1093/annonc/mdt138
8. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C (2013) Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol: Off J Eur Soc Med Oncol ESMO. doi: 10.1093/annonc/mdt136
9. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV (2013) Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. doi: 10.1016/j.eururo.2013.06.042
10. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS (2013) Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer. doi: 10.1016/j.ejca.2013.08.020
11. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2:e00499. doi: 10.7554/eLife.00499
12. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73(2):483-489. doi: 10.1158/0008-5472.CAN-12-3630
13. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res: Off J Am Assoc Cancer Res 17(18):5913-5925. doi: 10.1158/1078-0432.CCR-11-0728
14. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028-1038. doi: 10.1056/NEJMoa1315815
15. Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN (2013) AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther 12(9):1715-1727. doi: 10.1158/1535-7163.MCT-12-1174
16. Bradbury RH, Acton DG, Broadbent NL, Brooks AN, Carr GR, Hatter G, Hayter BR, Hill KJ, Howe NJ, Jones RD, Jude D, Lamont SG, Loddick SA, McFarland HL, Parveen Z, Rabow AA, Sharma-Singh G, Stratton NC, Thomason AG, Trueman D, Walker GE, Wells SL, Wilson J, Wood JM (2013) Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett 23(7):1945-1948. doi: 10.1016/j.bmcl.2013.02.056
17. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol: Off J Am Soc Clin Oncol 26(7):1148-1159. doi: 10.1200/JCO.2007.12.4487
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026
19. Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC (2008) Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol: Off J Am Soc Clin Oncol 26(2):190-195. doi: 10.1200/JCO.2007.12.7712
20. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res: Off J Am Assoc Cancer Res 10(20):6897-6904. doi: 10.1158/1078-0432.CCR-04-0378
21. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP (2014) Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res: Off J Am Assoc Cancer Res 20(15):4075-4085. doi: 10.1158/1078-0432.CCR-14-0292
22. Taplin ME, Chi K, Chu F, Cochran J, Edenfield W, Eisenberger M, Emmenegger U, Heath E, Hussain A, Koletsky A, Lipsitz D, Nordquist L, Pili R, Rettig M, Sartor O, Shore N, Dhillon R, Roberts J, Montgomery B (2014) Galeterone in 4 patient populations of men with CRPC: Results from ARMOR2. ESMO conference 2014, Madrid Abstract 757O
23. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Chen Y, Roeser JC, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Judith Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 32:5s, 2014 (suppl; abstr 5001)
24. Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y (2014) Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5(6):1646-1656
25. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123(7):2948-2960. doi: 10.1172/JCI66398
26. Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hessein M, Hsing M, Singh K, LeBlanc E, Dehm S, Guns ES, Cherkasov A, Rennie PS (2014) Selectively targeting the DNA binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. doi: 10.1074/jbc.M114.553818